NO20061907L - Benzazepinderivater som Mao-B inhibitorer - Google Patents

Benzazepinderivater som Mao-B inhibitorer

Info

Publication number: NO20061907L
Authority: NO; Norway
Prior art keywords: mao; inhibitors; benzazepine derivatives; derivatives; implicated
Prior art date: 2003-10-23

Application number

NO20061907A

Other languages

English (en)

Norwegian (no)

Inventor

Wolfgang Wostl

Rosa Maria Rodriguez Sarmiento

Andrew William Thomas

Rene Wyler

Synese Jolidon

Original Assignee

Hoffmann La Roche

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-10-23

Filing date

2006-04-28

Publication date

2006-07-12

2006-04-28 Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche

2006-07-12 Publication of NO20061907L publication Critical patent/NO20061907L/no

Links

150000008038 benzoazepines Chemical class 0.000 title abstract 2
239000003112 inhibitor Substances 0.000 title 1
102000010909 Monoamine Oxidase Human genes 0.000 abstract 1
108010062431 Monoamine oxidase Proteins 0.000 abstract 1
201000010099 disease Diseases 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
239000003814 drug Substances 0.000 abstract 1
230000005764 inhibitory process Effects 0.000 abstract 1
238000004519 manufacturing process Methods 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
230000002265 prevention Effects 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D223/16—Benzazepines; Hydrogenated benzazepines
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/06—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom containing only hydrogen and carbon atoms in addition to the ring nitrogen atom
- C07D213/16—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom containing only hydrogen and carbon atoms in addition to the ring nitrogen atom containing only one pyridine ring
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Pain & Pain Management (AREA)
Psychiatry (AREA)
Physical Education & Sports Medicine (AREA)
Epidemiology (AREA)
Addiction (AREA)
Orthopedic Medicine & Surgery (AREA)
Psychology (AREA)
Ophthalmology & Optometry (AREA)
Rheumatology (AREA)
Hospice & Palliative Care (AREA)
Nutrition Science (AREA)
Physiology (AREA)
Dermatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Plural Heterocyclic Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Other In-Based Heterocyclic Compounds (AREA)

NO20061907A 2003-10-23 2006-04-28 Benzazepinderivater som Mao-B inhibitorer NO20061907L (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP03024297		2003-10-23
PCT/EP2004/011541 WO2005039591A1 (en)	2003-10-23	2004-10-14	Benzazepine derivatives as mao-b inhibitors

Publications (1)

Publication Number	Publication Date
NO20061907L true NO20061907L (no)	2006-07-12

Family

ID=34486095

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20061907A NO20061907L (no)	2003-10-23	2006-04-28	Benzazepinderivater som Mao-B inhibitorer

Country Status (19)

Country	Link
US (2)	US7173023B2 (de)
EP (1)	EP1680127B1 (de)
JP (1)	JP2007509094A (de)
KR (1)	KR100856141B1 (de)
CN (1)	CN100441188C (de)
AR (1)	AR046133A1 (de)
AT (1)	ATE411027T1 (de)
AU (1)	AU2004283452A1 (de)
BR (1)	BRPI0415842A (de)
CA (1)	CA2543287A1 (de)
CO (1)	CO5680409A2 (de)
DE (1)	DE602004017206D1 (de)
IL (1)	IL174845A0 (de)
MX (1)	MXPA06004307A (de)
NO (1)	NO20061907L (de)
RU (1)	RU2006117366A (de)
TW (1)	TWI254707B (de)
WO (1)	WO2005039591A1 (de)
ZA (1)	ZA200603177B (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ATE441417T1 (de)	2002-12-20	2009-09-15	Glaxo Group Ltd	Benzoädüazepinderivate für die behandlung von neurologischen krankheiten
GB0408083D0 (en) *	2004-04-08	2004-05-12	Glaxo Group Ltd	Novel compounds
WO2007149728A2 (en) *	2006-06-20	2007-12-27	Alcon Research, Ltd.	Aryl and heteroaryl tetrahydrobenzazepine derivatives and their use for treating glaucoma
FR2932800B1 (fr) *	2008-06-20	2015-02-20	Servier Lab	Nouveau procede de synthese de la 7,8-dimethoxy-1,3-dihydro- 2h-3-benzazepin-2-one, et application a la synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable
KR101220182B1 (ko) *	2009-02-25	2013-01-11	에스케이바이오팜 주식회사	치환된 아졸 유도체 화합물, 이를 포함하는 약제학적 조성물 및 이를 이용한 파킨슨씨 병 치료방법
SG11201504704TA (en)	2013-03-14	2015-07-30	Dart Neuroscience Llc	Substituted naphthyridine and quinoline compounds as mao inhibitors
CN114437068A (zh) *	2022-02-21	2022-05-06	深圳市儿童医院	一种萘啶衍生物及其作为单胺氧化酶抑制剂的用途
CN119977904A (zh) *	2025-02-18	2025-05-13	合肥工业大学	一种苯并氧（碳/硫）氮杂䓬类化合物及其在医学上的应用

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE1003753B (de)	1953-11-07	1957-03-07	Dr Karl Kindler	Verfahren zur Herstellung von N-Dialkylaminoacylaminophenolaethern
US3719669A (en) *	1972-03-27	1973-03-06	Pennwalt Corp	Amino(or amido)-phenyl-alkyl-benzazepine analgesics and narcotic antagonists
US4210749A (en) *	1974-11-12	1980-07-01	Pennwalt Corporation	Substituted 1,2,4,5-tetrahydro-3H,3 benzazepines
US4348393A (en) *	1978-06-09	1982-09-07	Delalande S.A.	N-Aryl oxazolidinones, oxazolidinethiones, pyrrolidinones, pyrrolidines and thiazolidinones
FR2500831A1 (fr)	1981-02-27	1982-09-03	Delalande Sa	Nouvelles n-aryl-oxazolidinones et -pyrrolidinones
US4524206A (en) *	1983-09-12	1985-06-18	Mead Johnson & Company	1-Heteroaryl-4-(2,5-pyrrolidinedion-1-yl)alkyl)piperazine derivatives
CA1261335A (en) *	1984-08-29	1989-09-26	Hoffmann-La Roche Limited/Hoffmann-La Roche Limitee	Ethylenediamine monoamide derivatives
CN86106435A (zh) *	1985-09-24	1987-05-27	舍林股份公司	咪唑啉基衍生物，其制备方法和含有这类化合物的具有除草作用的制剂
JPS6259973U (de)	1985-10-04	1987-04-14
CA1332151C (en)	1988-01-28	1994-09-27	Roman Amrein	Use of a benzamide to treat cognitive disorder
DE3834861A1 (de) *	1988-10-13	1990-04-19	Basf Ag	Arylalkoxycumarine, verfahren zu ihrer herstellung und diese enthaltende therapeutische mittel
JPH02142774A (ja)	1988-11-25	1990-05-31	Mitsui Toatsu Chem Inc	２−（４−置換フェニル）イミダゾリノン類、その製造法、およびそれらを有効成分として含有する除草剤
FR2645019A1 (de)	1989-03-30	1990-10-05	Fournier Innovation Synergie
IL94466A (en)	1989-05-25	1995-01-24	Erba Carlo Spa	Pharmaceutical preparations containing the history of A-amino carboxamide N-phenylalkyl are converted into such new compounds and their preparation
JPH0667915B2 (ja)	1990-09-17	1994-08-31	ファイザーインク	５−トリフルオロアシルアミノ−２−アリールオキサゾール
JPH04295470A (ja)	1991-03-22	1992-10-20	Wakamoto Pharmaceut Co Ltd	モノアミンオキシダーゼ−ｂ酵素阻害活性を有する１，２，４−オキサジアゾール誘導体及びその製造法
GB9119467D0 (en) *	1991-09-12	1991-10-23	Smithkline Beecham Corp	Chemical compounds
TW219935B (de) *	1991-12-25	1994-02-01	Mitsubishi Chemicals Co Ltd
JPH05262718A (ja)	1992-03-23	1993-10-12	Taisho Pharmaceut Co Ltd	５−置換アミノ−２−フェノキシスルホンアニリド化合物
US5317017A (en) *	1992-09-30	1994-05-31	Merck & Co., Inc.	N-biphenyl-3-amido substituted benzolactams stimulate growth hormone release
GB9306886D0 (en) *	1993-04-01	1993-05-26	Erba Carlo Spa	Substituted (arylakoxybenzyl) aminopropanamide derivatives and process for their preparation
GB9313365D0 (en) *	1993-06-29	1993-08-11	Roussel Lab Ltd	Chemical compounds
US6448269B1 (en) *	1993-07-22	2002-09-10	Eli Lilly And Company	Glycoprotein IIb/IIIa antagonists
IL110172A (en)	1993-07-22	2001-10-31	Lilly Co Eli	Bicyclic compounds and pharmaceutical compositions containing them
US6137002A (en) *	1993-07-22	2000-10-24	Eli Lilly And Company	Glycoprotein IIb/IIIa antagonists
US5731324A (en) *	1993-07-22	1998-03-24	Eli Lilly And Company	Glycoprotein IIb/IIIa antagonists
ES2098186B1 (es)	1995-02-09	1998-02-01	Consejo Superior Investigacion	Composiciones farmaceuticas a base de aminometilindoles para su aplicacion terapeutica como neuroprotectores en las enfermedades de parkinson y alzheimer.
US5679715A (en)	1995-06-07	1997-10-21	Harris; Richard Y.	Method for treating multiple sclerosis
GB9515412D0 (en)	1995-07-27	1995-09-27	Pharmacia Spa	2-(4-substituted)-benzylamino-2-methyl-propanamide derivatives
WO1997033572A1 (en)	1996-03-15	1997-09-18	Somerset Pharmaceuticals, Inc.	Method for preventing and treating peripheral neurophathy by administering selegiline
TW498067B (en) *	1996-07-19	2002-08-11	Hoffmann La Roche	4-hydroxy-piperidine derivatives
ATE368665T1 (de)	1997-08-22	2007-08-15	Astrazeneca Ab	Oxindolylchinazolinderivate als angiogenesehemmer
WO1999014334A1 (en)	1997-09-19	1999-03-25	American Cyanamid Company	Peptides derived from the attachment (g) protein of respiratory syncytial virus
DE69842004D1 (de)	1997-11-21	2010-12-30	Purdue Neuroscience Co	Substituierte 2-aminoacetamide und anwendung davon
GB9727521D0 (en)	1997-12-31	1998-02-25	Pharmacia & Upjohn Spa	Substituted 2-benzylamino-2-phenyl-acetamide compounds
WO1999054279A1 (en)	1998-04-20	1999-10-28	Ortho-Mcneil Pharmaceutical, Inc.	Substituted amino acids as erythropoietin mimetics
DE19841895A1 (de)	1998-09-11	2000-03-23	Degussa	Neues Verfahren zur Herstellung von 3-Amino-2-oxo-pyrrolidinen, neue Zwischenprodukte und deren Verwendung
US6294694B1 (en)	1999-06-04	2001-09-25	Wisconsin Alumni Research Foundation	Matrix metalloproteinase inhibitors and method of using same
DE19952146A1 (de)	1999-10-29	2001-06-07	Boehringer Ingelheim Pharma	Arylalkane, Arylalkene und Aryl-azaalkane, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
WO2001034172A2 (en)	1999-11-05	2001-05-17	Vela Pharmaceuticals Inc.	Methods and compositions for treating reward deficiency syndrome
US6306911B1 (en)	2000-02-07	2001-10-23	Ortho-Mcneil Pharmaceutical, Inc.	Substituted amino acids as neutral sphingomyelinase inhibitors
US6667327B2 (en) *	2002-02-04	2003-12-23	Hoffmann-La Roche Inc.	Pyridine amido derivatives
US6660736B2 (en) *	2002-03-27	2003-12-09	Hoffmann-La Roche Inc.	Phthalimido derivatives and a process for their preparation
US6953787B2 (en) *	2002-04-12	2005-10-11	Arena Pharmaceuticals, Inc.	5HT2C receptor modulators
EP1501804B1 (de) *	2002-04-26	2009-08-26	F. Hoffmann-La Roche Ag	Isochinolinderivate als mao-b inhibitoren
ES2324214T3 (es) *	2002-05-29	2009-08-03	F. Hoffmann-La Roche Ag	Derivados de n-acilaminobenceno como inhibidores de la monoamina oxidasa b selectiva.
ATE441417T1 (de) *	2002-12-20	2009-09-15	Glaxo Group Ltd	Benzoädüazepinderivate für die behandlung von neurologischen krankheiten
WO2005042491A1 (en) *	2003-10-22	2005-05-12	Arena Pharmaceuticals, Inc.	Benzazepine derivatives and methods of prophylaxis or treatment of 5ht2c receptor associated diseases

2004
- 2004-10-14 WO PCT/EP2004/011541 patent/WO2005039591A1/en not_active Ceased
- 2004-10-14 CA CA002543287A patent/CA2543287A1/en not_active Abandoned
- 2004-10-14 EP EP04790400A patent/EP1680127B1/de not_active Expired - Lifetime
- 2004-10-14 AT AT04790400T patent/ATE411027T1/de not_active IP Right Cessation
- 2004-10-14 CN CNB2004800309236A patent/CN100441188C/zh not_active Expired - Fee Related
- 2004-10-14 AU AU2004283452A patent/AU2004283452A1/en not_active Abandoned
- 2004-10-14 KR KR1020067007779A patent/KR100856141B1/ko not_active Expired - Fee Related
- 2004-10-14 RU RU2006117366/04A patent/RU2006117366A/ru not_active Application Discontinuation
- 2004-10-14 JP JP2006536004A patent/JP2007509094A/ja active Pending
- 2004-10-14 DE DE602004017206T patent/DE602004017206D1/de not_active Expired - Fee Related
- 2004-10-14 MX MXPA06004307A patent/MXPA06004307A/es not_active Application Discontinuation
- 2004-10-14 BR BRPI0415842-3A patent/BRPI0415842A/pt not_active IP Right Cessation
- 2004-10-18 US US10/967,567 patent/US7173023B2/en not_active Expired - Fee Related
- 2004-10-20 TW TW093131855A patent/TWI254707B/zh not_active IP Right Cessation
- 2004-10-21 AR ARP040103808A patent/AR046133A1/es unknown
2006
- 2006-04-06 IL IL174845A patent/IL174845A0/en unknown
- 2006-04-18 CO CO06036626A patent/CO5680409A2/es not_active Application Discontinuation
- 2006-04-20 ZA ZA200603177A patent/ZA200603177B/en unknown
- 2006-04-28 NO NO20061907A patent/NO20061907L/no not_active Application Discontinuation
2007
- 2007-01-12 US US11/652,970 patent/US20070117791A1/en not_active Abandoned

Also Published As

Publication number	Publication date
MXPA06004307A (es)	2006-06-05
WO2005039591A1 (en)	2005-05-06
BRPI0415842A (pt)	2007-01-02
EP1680127B1 (de)	2008-10-15
ZA200603177B (en)	2007-09-26
JP2007509094A (ja)	2007-04-12
IL174845A0 (en)	2006-08-20
EP1680127A1 (de)	2006-07-19
CN100441188C (zh)	2008-12-10
KR100856141B1 (ko)	2008-09-03
KR20060061390A (ko)	2006-06-07
DE602004017206D1 (de)	2008-11-27
CN1871013A (zh)	2006-11-29
AR046133A1 (es)	2005-11-23
TWI254707B (en)	2006-05-11
TW200524875A (en)	2005-08-01
CA2543287A1 (en)	2005-05-06
RU2006117366A (ru)	2007-12-10
US20070117791A1 (en)	2007-05-24
CO5680409A2 (es)	2006-09-29
ATE411027T1 (de)	2008-10-15
AU2004283452A1 (en)	2005-05-06
US20050107360A1 (en)	2005-05-19
US7173023B2 (en)	2007-02-06

Legal Events

Date	Code	Title	Description
2010-05-31	FC2A	Withdrawal, rejection or dismissal of laid open patent application

Publication	Publication Date	Title
NO20084845L (no)	2009-02-03	2-pyrazinonderivater for behandling av sykdom eller tilstander der inhibiering av neutrofil elastaseaktivitetet er gunstig
NO20074592L (no)	2007-10-19	Acetylenyl-pyrazolo-pyrimidinderivater som mGluR2-antagonister
NO20051962L (no)	2005-05-19	Fenetanolaminderivater for behandling av respiratoriske sykdommer
WO2007127635A3 (en)	2008-03-13	Diketo-piperazine and piperidine derivatives as antiviral agents
NO20084872L (no)	2009-02-03	2-pyridonderivater for behandling av sykdom eller tilstander der inhibering av neutrofil elastaseaktivitet er gunstig
NO20083434L (no)	2008-08-12	Benzamid- og heteroarenderivater
NO20065456L (no)	2007-01-04	Substituerte morfolinforbindelser for behandling av sykdommer i sentralnervesystemet
NO20055421L (no)	2005-12-20	Kinolinderivater som fosfodiestrase-inhibitorer
NO20060324L (no)	2006-05-18	[1,8]Naftyridin-2-oner og relaterte forbindelser for behandling av Schizofreni
NO20081729L (no)	2008-05-16	Nye diazaspiroalkaner og deres anvendelse for behandling av CCR8-medierte sykdommer
NO20074258L (no)	2007-11-27	Pyridin-2-karboksamidderivater som MGLUR5 antagonister
NO20092342L (no)	2009-07-02	Azaspiroderivativater
NO20032820L (no)	2003-08-21	Oksybenzamidderivater som faktor XA inhibitorer
NO20081217L (no)	2008-04-15	Nye benzotiazolonderivater
NO20082643L (no)	2008-09-01	Isokinolinaminopyrazolderivater, deres fremstilling og anvendelse som farmasoytiske midler for behandling av kreft
NO20070258L (no)	2007-01-15	Benzyltriazolonforbindelser som ikke-nukleoside revers transkriptase inhibitorer
NO20054329L (no)	2005-11-21	Adamantanderivater, fremgangsmater for deres fremstilling og farmasoytiske sammensetninger som innbefatter slike
NO20073572L (no)	2007-09-12	Nye forbindelser
NO20044571L (no)	2004-10-22	Isokinolinderivater
EP1396493A4 (de)	2005-08-03	Heterocyclische verbindungen
DE602004008959D1 (de)	2007-10-25	Benzoäbüä1,4üdioxepinderivate
NO20070570L (no)	2007-04-10	Forbindelser.
NO20076682L (no)	2008-03-05	Nye pyridinanaloger
NO20065880L (no)	2006-12-20	3-Amino-l-arylpropylindoler som monoamin-gjenopptagelsesinhibitor
NO20073631L (no)	2007-09-12	Metasubstituerte tiazolidinoner, fremgangsmate for fremstilling og anvendelse av disse som legemiddel